Stock Fundamentals

Company Information

Company Name
Agenus Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00847G8042
CIK: 0001098972
CUSIP: 037032109
Currency: USD
Full Time Employees: 81
Phone: 781 674 4400
Fiscal Year End: December
IPO Date: Feb 04, 2000
Description:

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Address:

3 Forbes Road, Lexington, MA, United States, 02421-7305

Directors & Officers

Name Title Year Born
Dr. Garo H. Armen Ph.D. Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman 1953
Dr. Steven J. O'Day M.D., Ph.D. Chief Medical Officer 1961
Dr. Jennifer S. Buell Ph.D. Director and President & CEO of MiNK Therapeutics 1975
Craig Winter Chief Information Officer NA
Mr. Zack Armen Vice President of Investor Relations & Corporate Development NA
Ms. Stefanie Perna-Nacar Chief Communications & Government Relations Officer NA
Ms. Tracy Mazza Clemente Chief People Officer NA
Dr. Todd Jude Yancey M.D. Member of Advisory Board & Chief Strategic Advisor NA
Dr. Robin G. Taylor M.B.A., Ph.D. Chief Commercial Officer NA
Dr. Kamel Djazouli M.D. Head of Medical Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 15, 2024 Garo H Armen N/A Purchase 25.00K $13.00 $325.00K
Oct 16, 2023 Agenus Inc N/A Purchase 21.00 $22.00 $462.00
Oct 12, 2023 Agenus Inc N/A Purchase 158.00 $22.00 $3.48K
Oct 04, 2023 Agenus Inc N/A Purchase 750.00 $21.80 $16.35K
Aug 28, 2023 Agenus Inc N/A Purchase 640.00 $29.00 $18.56K
Aug 24, 2023 Agenus Inc N/A Purchase 8.51K $30.80 $262.17K
May 10, 2023 Agenus Inc N/A Purchase 1.10K $30.20 $33.31K
May 05, 2023 Agenus Inc N/A Purchase 5.01K $19.00 $95.19K
May 03, 2023 Agenus Inc N/A Purchase 6.43K $21.60 $138.97K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 2.83M Dec 31, 2025 6.80% $0.00 10.17%
Vanguard Capital Management, LLC 1.44M Mar 31, 2026 3.46% $0.00 0.00%
Vanguard Portfolio Management, LLC 1.20M Mar 31, 2026 2.87% $0.00 0.00%
Siren, L.L.C. 1.06M Mar 31, 2026 2.56% $0.10 0.00%
Marshall Wace Asset Management Ltd 688.20K Mar 31, 2026 1.65% $0.00 368.80%
BlackRock Inc 545.66K Mar 31, 2026 1.31% $0.00 -2.27%
Geode Capital Management, LLC 348.40K Mar 31, 2026 0.84% $0.00 -6.53%
Morgan Stanley - Brokerage Accounts 295.82K Mar 31, 2026 0.71% $0.00 3.72%
Renaissance Technologies Corp 285.65K Mar 31, 2026 0.69% $0.00 -47.45%
Man Group PLC 278.98K Mar 31, 2026 0.67% $0.00 144.28%
UBS Group AG 234.44K Mar 31, 2026 0.56% $0.00 97.31%
Acadian Asset Management LLC 215.05K Mar 31, 2026 0.52% $0.00 49,564.43%
Vanguard Fiduciary Trust Co 200.50K Mar 31, 2026 0.48% $0.00 0.00%
Connor Clark & Lunn Inv Mgmt Ltd 198.50K Mar 31, 2026 0.48% $0.00 192.09%
Two Sigma Investments LLC 170.92K Mar 31, 2026 0.41% $0.00 45.94%
Panagora Asset Management Inc 163.15K Mar 31, 2026 0.39% $0.00 0.00%
Jump Financial LLC 157.20K Mar 31, 2026 0.38% $0.01 -7.75%
State Street Corp 156.18K Mar 31, 2026 0.38% $0.00 13.68%
Walleye Trading Advisors, LLC 120.57K Mar 31, 2026 0.29% $0.00 -2.34%
Bank of America Corp 118.78K Mar 31, 2026 0.29% $0.00 796.74%

Shares Statistics

Shares Outstanding: 41.64M
Shares Float: 38.85M
% Insiders: 672.30%
% Institutions: 2,369.90%
Short % Float: 14.58%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.02M 2.45% ▲ 0.00% Apr 30, 2026
2 Vanguard Strategic Equity Inv 511.81K 1.23% ▲ 0.00% Mar 31, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 386.79K 0.93% ▲ 0.00% Apr 30, 2026
4 Vanguard Explorer Inv 290.65K 0.70% ▲ 0.00% Mar 31, 2026
5 Acuitas US Microcap Strategy 209.68K 0.50% ▲ 71.64% Mar 31, 2026
6 Vanguard Strategic Small-Cap Equity Inv 205.35K 0.49% ▲ 0.00% Mar 31, 2026
7 SEI Tax-Managed Small/Mid Cap F (SIMT) 170.90K 0.41% ▲ 153.55% May 31, 2026
8 Fidelity Extended Market Index 163.92K 0.39% ▲ 17.97% Apr 30, 2026
9 Vanguard VIF Small Co Gr 153.74K 0.37% ▼ 22.20% Mar 31, 2026
10 SEI Small Cap II A (SIIT) 84.70K 0.20% ▼ 5.57% May 31, 2026

Valuation Metrics

Enterprise Value: $145.58M
Trailing P/E: 1.63
Forward P/E: 1.49

Financial Highlights

Market Cap: $139.50M
EBITDA: $15.19M
P/E Ratio: $1.63
PEG Ratio: $1.44
Book Value: $-5.74
Earnings/Share: $2.05
Profit Margin: 52.16%
Operating Margin: 44.62%
ROA (TTM): 2.53%
ROE (TTM): -1,278.83%
Revenue (TTM): $123.87M
Revenue/Share (TTM): $3.74
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 40.20%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 0.41x -0.58x 2.23x -0.37x 2.51x
2024-12-31 0.21x -0.12x 2.35x -1.02x -0.40x
2023-12-31 0.44x -1.07x 1.47x -1.63x -1.09x
2022-12-31 1.13x -0.28x 1.13x -2.90x -0.09x
2021-12-31 2.12x 0.34x 0.90x 0.39x 0.37x
2020-12-31 0.88x -0.10x 1.99x -1.92x -0.19x
2019-12-31 0.71x -0.07x 2.49x -1.69x -0.24x
2018-12-31 1.10x -0.08x 2.28x -4.90x -0.10x
2017-12-31 1.30x -2.15x 1.55x -5.50x -1.70x
2016-12-31 2.24x -3.34x 1.25x -6.21x -1.25x
2015-12-31 6.36x 1.62x 0.71x -12.23x -1.35x
2014-12-31 4.62x 0.26x 0.69x -34.34x -0.15x
2013-12-31 2.74x -1.98x 1.13x -10.29x -0.36x
2012-12-31 4.70x -2.99x 1.35x -1.43x -7.02x
2011-12-31 2.53x -1.58x 2.05x -4.53x -1.96x
2010-12-31 3.85x -2.33x 1.48x -4.47x -2.51x
2009-12-31 5.89x -2.92x 1.37x -5.18x -2.38x
2008-12-31 5.07x -2.84x 1.42x -7.45x -1.80x
2007-12-31 2.48x -1.65x 2.06x -6.68x -2.94x
2006-12-31 4.66x -4.34x 1.24x -15.39x -1.76x
2005-12-31 3.50x 1.70x 0.69x -24.94x -0.83x
2004-12-31 4.82x 0.09x 0.20x -131.27x -0.16x
2003-12-31 4.22x 0.15x 0.25x -274.15x -0.26x
2002-12-31 6.36x 0.01x 0.13x -157.12x -0.01x
2001-12-31 3.95x 0.08x 0.19x -60.33x -0.16x
2000-12-31 11.80x 0.04x 0.09x -62.84x -0.20x
1999-12-31 21.68x 0.02x 0.08x N/A -0.04x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AGEN.US!